UBS Group
NTLA icon

UBS Group’s Intellia Therapeutics NTLA Stock Holding History

UBS Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-34,000
Closed -$2.47M – 10723
2022
Q1 		$2.47M Buy
+34,000
New +$2.88M ﹤0.01% 3237

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS Group's NTLA Position: Q1 2026 in Review

UBS Group increased its Intellia Therapeutics (NTLA) stake by 213% in Q1 2026, buying an estimated $23.3M and bringing the position to 2,689,486 shares worth $34.5M. The position accounts for 0.01% of the portfolio, ranked #2019.

UBS Group first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • UBS Group held 2,689,486 shares of Intellia Therapeutics worth $34.5M as of Q1 2026.
  • UBS Group bought 1,829,934 Intellia Therapeutics shares in Q1 2026, an estimated $23.3M.
  • Intellia Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #2019 holding.
  • UBS Group first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.